Sorry, you need to enable JavaScript to visit this website.

U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic NSCLC

September 28, 2018
On September 27, 2018, the U.S. FDA approved VIZIMPRO® [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. The safety and efficacy of VIZIMPRO was demonstrated in the randomized, open-label, phase 3 study, ARCHER 1050 (NCT01774721). Please see the full press release via the link below for further details.